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Abstract 
Background: Percutaneous atrial septal defect (ASD) closure is a routine procedure 
to prevent right ventricular failure, pulmonary hypertension, or paradoxical embolism. 
The latter is the typical reason for percutaneous patent foramen ovale (PFO) closure. 
Atrial enlargement represents a risk for developing atrial fibrillation (AF).  
Percutaneous left atrial appendage (LAA) closure is emerging as a preventive therapy 
for patients in AF who suffered from a previous stroke or bleeding (secondary 
prevention) or patients without previous stroke or bleeding (primary prevention). 
Percutaneous septal closure, particularly that of large ASDs, may inhibit future 
percutaneous left atrial access when required for LAA closure. Reported herein is the 
feasibility and safety of concomitant percutaneous closure of the LAA and a septal 
shunt, mostly large ASDs, in patients without AF, in the sense of primary primary 
preventive LAA closure. The first “primary” relates to “in anticipation of AF” and 
potentially also for “for prevention of AF”. The second “primary” relates to 
“prevention of stroke or bleeding”. 
Methods: Thirteen consecutive patients, older than 40 years without any clinical or 
electrocardiographic evidence of AF, underwent percutaneous closure of large ASDs 
 or PFOs in the presence of enlarged atria at the university hospitals of Bern and 
Zurich between April 2013 and June 2015. They concomitantly received primary 
primary preventive LAA closure after informed consent.  
Results Mean patient age was 58 ± 9 years (46% male). Procedural success was 
achieved in all patients and no major adverse events occurred acutely or during the 
following 2.0 ± 0.8 years. No patient developed AF. 
Conclusions: Concomitant closure of ASD or PFO in the presence of enlarged atria 
and LAA for primary primary prevention appears feasible and safe but has yet to 
prove its justification. 
Key words: atrial fibrillation, atrial septal defect closure, patent foramen ovale 
closure, left atrial appendage closure 
 
 
Introduction 
Atrial septal defect (ASD) is one of the most frequent congenital heart defects 
[1]. While the only risk of small ASDs is paradoxical embolism, sequelae of larger 
ASDs comprise pulmonary hypertension, congestive heart failure, and atrial 
arrhythmia, in particular atrial fibrillation (AF) [2–5]. Percutaneous ASD closure is 
the treatment of choice for ASDs to prevent such adverse outcome and to improve 
exertional dyspnea [6–8]. Percutaneous ASD closure is an overall safe procedure but 
it carries a potential risk for developing AF by device irritation of the septum [9–11]. 
Although such new onset AF typically occurs only in the first few weeks after device 
implantation [9, 12], patients undergoing percutaneous closure of large ASDs are 
temporarily at a double risk for developing AF, 1) due to septal device irritation and 
2) due to the preexisting atrial enlargement. Subsequent reduction of atrial diameters 
after shunt elimination reduces the risk for AF. A net benefit in that respect can be 
expected but the overall risk for AF of such patients remains elevated. The situation is 
similar for patients with a patent foramen ovale (PFO) and enlarged atria. 
In AF, left atrial appendage (LAA) closure has emerged as an alternative to 
medical therapy in the form of chronic oral anticoagulation (COA) for stroke or 
bleeding prevention. While closure of the LAA comes at the price of 2–7% procedural 
adverse events, it shows a significant reduction in major bleeding events at a similar 
 stroke rate compared to COA [13–16]. After 4 years of follow-up, closure of the LAA 
even showed significantly improved survival in randomized comparisons [17, 18].  
Closure of the LAA so far has been exclusively performed in patients with 
documented AF, either for primary prevention (patients with AF without previous 
embolic ischemic event or bleeding) or secondary prevention (patients with AF with a 
previous embolic ischemic event or bleeding).  
Percutaneous closure of septal defects, particularly large ASDs, hinders future 
percutaneous transseptal left atrial access although it remains possible at least in the 
case of smaller ASD [19] or PFO devices [20]. Even if such patients never had AF, 
their risk for developing AF during follow-up is 2-fold higher after ASD closure than 
that of the general population [21] and also increased after PFO closure in the 
presence of enlarged atria. 
Herein reported is the first experience with concomitant percutaneous closure 
of LAA at the time of closure of ASDs or PFOs in the presence of enlarged atria in 
patients without history of AF. They were considered at increased risk for later AF, 
particularly in the initial phase after septal shunt closure due to septal device irritation 
while atrial dimensions have not yet shrunk after volume unload. It is referred to in 
this procedure as primary primary preventive LAA closure, i.e., LAA closure for 
primary prevention (in anticipation of AF or even preventing AF) and for primary 
prevention of stroke or bleeding, should AF occur. 
 
METHODS 
Population 
This is a retrospective study of consecutive patients (≥ 40 years) undergoing 
percutaneous closure of a large ASD (≥ 20 mm) or a PFO with large atria (left atrium 
(LA) ≥ 40 mm, parasternal long axis) and at the same time of the LAA. Patients 
neither had clinical or electrocardiographic signs of prior AF nor an AF associated 
embolic ischemic or bleeding event. In the patients with prior ischemic events, AF 
had been excluded by long-term electrocardiogram (ECG). Patients consented to both 
procedures (ASD closure and LAA closure) separately and also to data collection. The 
potential benefits and risks of primary primary preventive LAA closure was discussed 
extensively with the patients. The local institutional review boards approved data 
collection of clinically indicated investigations during follow-up. The procedures 
were performed at the university hospitals of Bern and Zurich. Demographic and 
 clinical characteristics, including risk for stroke and major bleeding (CHA2DS2-VASc 
score, HAS-BLED score), procedural data, and outcome data of in-hospital and 
follow-up periods were captured from medical records and patient contact. 
 
Procedure 
All procedures were performed under fluoroscopy guidance without 
echocardiography [15, 22, 23]. All patients had had transesophageal 
echocardiography (TEE) during their workups. Computer tomography was not used. 
Oral antibiotics (2–3 doses) were given before and after the procedure and all patients 
received 5000 units of intravenous heparin at the beginning of the procedure. All 
procedures were done using Amplatzer devices (Amplatzer Cardiac Plug (ACP), 
Amplatzer Amulet Occluder, Amplatzer Septal Occluder (ASO), Amplatzer 
Cribriform Occluder, or Amplatzer PFO Occluder, Abbott, St. Paul, MN, USA). 
Figures 1–4 provide examples. LAA closure was performed before septal closure. 
After crossing the septal defect from the right femoral vein, a 0.035” Backup wire 
(Boston Scientific, Natick, MA, USA) was placed in the LA. A 34 mm Amplatzer 
sizing balloon was placed across ASDs and inflated to aid eyeball sizing of the defect. 
The balloon was removed. Over the Backup wire, the 14 French (F) 45° × 45° 
Amplatzer TorqVue delivery sheath was introduced. The LAA was engaged in a right 
anterior oblique (RAO) view and contrast injections were performed in RAO caudal 
and cranial views. Sizing was done by eyeballingthe outer diameter of the delivery 
sheath (12 F: 4.5 mm, 13 F: 5.0 mm, and 14 F: 5.5 mm) served as reference. About 
20–50% oversizing was the rule [15]. Stability of the device was assessed by a tug test 
and by angiographic imaging with contrast medium injections in 2 views showing the 
device in profile without overlap of the 2 device components. After release of the 
LAA occluder, the TorqVue sheath was left in the LA and the appropriately sized 
septal occluder (aiming for at least 30% oversizing in ASDs) was attached to the same 
delivery cable and introduced through the sheath. In case of ASDs, the left atrial disc 
was fully and the right atrial disc partially deployed in the LA. This technique forces 
the ASO to self-center in the defect. The pulling of the right disc trough, the defect 
was observed based on the migrating of the lower device indentation in a left anterior 
oblique (LAO) projection before the right atrial disc was fully deployed. Correct 
device position was confirmed by LAO contrast medium injections and a robust 
wiggle of the device. The sheath was removed and the puncture site was manually 
 compressed by the patient unless a simultaneous arterial puncture mandated 
compression by a medical person. Before discharge the same or the following day, 
transthoracic echocardiography was performed to assure the correct position of the 
devices and to exclude pericardial effusion. There were no recommendations for 
physical restrictions of any sort. 
Post interventional antithrombotic regimen comprised clopidogrel 75 mg for 
1–3 months and acetylsalicylic acid 100 mg for 5–6 months. Control TEE was 
recommended after 3–6 months to assess for device thrombi and residual shunts or 
leaks. 
 
Outcome 
The composite endpoint was defined according to Valve Academic Research 
Consortium (VARC)-2 criteria [24]. The primary safety endpoint was defined as 
death related to closure of the LAA, procedure-related ischemic stroke, hemorrhagic 
stroke, cardiac tamponade, need for urgent surgery (e.g., due to embolization of the 
device, repair of procedure-related injury, or bleeding) and major or life-threatening 
bleeding (according to VARC-2 criteria). The primary efficacy endpoint was defined 
as stroke (non-disabling, disabling, ischemic, or hemorrhagic), systemic embolization, 
or cardiovascular or unexplained death. New-onset of AF was looked for clinically 
and by (24-h) ECG. Clinical follow-up data were obtained reviewing medical records 
and by contacting patients.  
 
Statistical analysis  
Data are expressed as mean and standard deviation for continuous variables 
and as number and percentage for categorical variables. Analysis was performed 
using a standard statistical software program (SPSS, version 23; IBM, Armonk, NY, 
USA).  
 
Results 
Baseline characteristics 
Thirteen patients were included between April 2013 and June 2015. Patients 
were 58 ± 9 years old (54% women). Baseline characteristics are described in Table 1. 
No patient had any history of AF. Three patients had a previous history of ischemic 
 cerebrovascular events. The total procedural fluoroscopy time was 16 ± 8 min (Table 
2). 
 
Device success 
In all patients ASD or PFO and LAA closures were successful. In 1 patient 2 
ASDs and in 1 patient, a PFO in addition to an ASD were found and closed with 2 
separate devices (Figs. 2, 3).No periprocedural complications occurred (Table 2).  
 
Clinical follow-up 
Length of hospital stay was 1 night in 9 patients and the remaining 4 patients 
were discharged the same day. TEE follow-up was available after 6.7 ± 2.0 months in 
10 patients. No device-related complications occurred (Table 3). One patient needed a 
re-intervention because of 2 residual ASD shunts at follow up. Re-intervention was 
successfully performed under fluoroscopy only using a 25 mm and a 18 mm PFO 
Occluder at 6 months after initial procedure. At clinical follow-up of 2.0 ± 0.8 years, 
no adverse events had occurred, no patient had reached a primary safety or efficacy 
endpoint, and at latest contact 91% of patients were on no anticoagulant or antiplatelet 
medication and 9% still acetylsalicylic acid (Table 4). The patients were asked for 
clinical symptoms of AF and all postinterventional ECGs were screened for AF. No 
patient had developed AF. 
 
Discussion 
Atrial fibrillation is the most common sustained cardiac arrhythmia [25] and is 
associated with substantial mortality and morbidity, particularly due to stroke [26]. 
ASD closure is advocated for prevention of stroke (paradoxical or secondary to AF) 
or heart failure due to volume overload. PFO closure is used for prevention of 
paradoxical stroke. LAA closure is indicated for prevention of stroke or bleeding in 
patients with AF [13–18]. 
The present study reports the feasibility and safety of primary primary 
preventive LAA closure during percutaneous ASD or PFO closure in patients with 
enlarged atria but no AF. It proved technically successful and safe but efficacy of our 
approach cannot be determined. No patient developed AF and therefore the potential 
of preventing embolic ischemia or bleeding because of the obviated need for oral 
anticoagulation remains unknown. 
 A large nationwide study of Nyboe et al. [21] included 1168 patients with 
ASD who were followed-up over a long-term period. The risk of developing AF was 
up to 10-fold in comparison to the general population. In case of conservative 
management, the stroke risk was 2.6-fold. In case of ASD closure, the stroke was 
reduced to 2-fold. This can be due to both, the elimination of paradoxical embolism 
and the reduction of atrial sizes. Yet, the risk of AF-associated stroke remains 
elelvated [21].  
Atrial fibbrilation with the need for COA is expected to occur with a certain 
frequency in patients at some point in time after septal defect closure while they were 
still in sinus rhythm [9, 27]. Age  > 40 years is a well-known risk factor for AF after 
ASD closure [28]. Moreover, ASD closure devices can trigger new-onset AF in the 
early phase. In the later phase they may reduce the risk of AF as the atria shrink after 
elimination of the shunt [10, 11]. Large devices in the interatrial septum may render 
percutaneous LAA closure intricate or downright impossible.  
Chronic oral anticoagulation has been proven to effectively prevent 
thromboembolic strokes but there is a risk of serious bleeding which deters many 
patients from taking this therapy [29]. Therefore, alternative treatment options for 
stroke prevention in patients with AF with increased stroke risk are needed. Closure 
of the LAA has emerged as promising [13, 30]. 
Left atrial appendage closure in the sense of primary primary prevention has 
the potential to avoid future strokes in case new-onset AF goes undetected on top of 
the potential to avoid major bleeding in case a patient requires COA for AF during 
follow-up. However as is inherent to every preventive intervention, the risk and cost 
of the combined and partially preventive intervention may become unjustified, in case 
AF never develops during follow-up. This concern is alleviated by the safety of such 
an approach which is apparent from these data. 
 
Limitations of the study 
The study has several limitations. It is a retrospective study and not a 
randomized trial and therefore selection bias is evident. The sample size is small. 
Furthermore, none of these patients developed AF during the relatively short 
observation period. More patients and longer follow-up are required to derive a 
clinically important message. 
 
 Conclusions 
This study demonstrates feasibility of primary primary preventive LAA 
closure during percutaneous closure of large ASDs or PFOs with atrial enlargement in 
patients without AF. In this series no adverse safety events occurred. The idea is to 
prepare such patients for the likely event of later AF. ASD closure alone with a large 
septal device renders it difficult if not impossible to later perform a transseptal 
puncture for LAA closure.  
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Table 1. Baseline characteristics (n = 13). 
Characteristics 
Age [years] 58.2 ± 9.1 
Body mass index [kg/m
2
] 27.0 ± 4.4 
Women 7 (54%) 
CHADS2 score 1.2 ± 1.3 
CHA2DS2-VASc score 1.92 ± 1.7 
HAS-BLED score 0.85 ± 1.1 
Atrial rhythm (including history) 
Atrial fibrillation (paroxysmal or permanent) 0 (0%) 
Atrial flutter 0 (0%) 
Clinical features 
Prior ischemic stroke 3 (23%) 
Coronary artery disease 0 (0%) 
Valvular heart disease 0 (0%) 
Renal function (mean eGFR, in ml/min/1.73 m
2
) 97 ± 24 
Anti-thrombotic therapy prior to laac 
Acetylsalicylic acid 3 (23%) 
Platelet inibitors other than acetylsalicylic acid 0 (0%) 
Chronic oral anticoagulation 0 (0%) 
Echocardiographic data 
Systolic left ventricular ejection fraction [%] 65 ± 2 
Left atrial diameter (PLAX echo, mm) 42 ± 5 
Values are n (%) or mean ± standard deviation; eGFR — estimated glomerular 
filtration rate; PLAX — parasternal long axis 
 
 
 Table 2. Intervention (n = 13). 
Procedural characteristics 
Flouroscopy time [min] 16 ± 8 
Amplatzer Cardiac Plug 6 (20 ± 3, 16–24 mm) 
Amplatzer Amulet Occluder 7 (21 ± 4, 16–25 mm) 
Amplatzer Septal Occluder 10 (34 ± 6, 24–40 mm)  
Amplatzer Cribriform Occluder 1 (30 mm) 
Amplatzer PFO Occluder 2 (25 mm) 
Implantation attempts 1.0 ± 0.0 
Concomittant procedures 
Coronary angiography 12 (92%) 
Perirocedural success and adverse events 
Procedural success  13 (100%) 
Combined safety endpoint* 0 (0%) 
*Composite of death, stroke, clinically relevant pericardial 
effusion, VARC-2 life-threatening or major bleeding, VARC-2 
major access vessel complication, device embolization, VARC-2 
severe kidney injury, or bailout surgery. 
Values are number (%) or mean ± standard deviation; PFO — 
patent foramen ovale; VARC — Valve Academic Research 
Consortium 
 
 
Table 3. Postprocedural data and follow-up transesophageal echocardiography (TEE). 
Post procedure in-hospital (n = 13) 
Hospital stay [days] 0.8±0.4 
Same day discharge 4 (31%) 
Pericardial effusion 0 (0%) 
Antithrombotic therapy (n = 13) 
Acetylsalicylic acid 12 (92%) 
Platelet inibitors other than acetylsalicylic acid 12 (92%) 
Dual antiplatelet therapy 12 (92%) 
 Vitamin K antagonists 0 (0%) 
Non vitamin K dependant oral anticoagulants  0 (0%) 
TEE (n = 10) 
 
Duration from intervention [months] 6.7 ± 2.0 
All devices in correct position 10 (100%)  
Late pericardial effusion 0 (0%) 
Late device embolization 0 (0%) 
Device thrombus (any) 0 (0%) 
Procedural success at TEE follow-up 8 (100%) 
Shunt or leak > 5 mm 1 (10%) 
Shunt or leak < 5 mm 2 (20%) 
Values are number (%) or mean ± standard deviation 
 
 
Table 4. Clinical follow-up (n = 13). 
Long-term clinical follow-up 13 (100%) 
Duration from procedure (years) 2.0 ± 0.8 
Antithrombotic therapy 
Acetylsalicylic acid 1 (9%) 
Other platelet inibitors 0 (0%) 
Dual antiplatelet therapy 0 (0%) 
Vitamin K antagonists 0 (0%) 
Non vitamin K dependant oral anticoagulants 0 (0%) 
Clinical outcome 
All-cause death 0 (0%) 
All-cause stroke 0 (0%) 
All-cause transient ischemich attack 0 (0%) 
Myocardial infarction 0 (0%) 
Systemic embolism 0 (0%) 
Venous thrombosis / pulmonary embolism 0 (0%) 
Fatal, lifethreatening, or major bleeding 0 (0%) 
Hospitalization 0 (0%) 
 Primary safety endpoint 0 (0%) 
Primary efficacy endpoint 0 (0%) 
Values are n (%) or mean ± standard deviation 
 
 
Figure 1. Simultaneous closure of the left atrial appendage (LAA) and an atrial septal 
defect (ASD) in a 55-year-old male with exertional dyspnea and a newly detected 
large ASD secundum but no history of atrial fibrillation. A. Overinflated 34 mm 
Amplatzer sizing balloon in ASD, measuring 38 mm at the waist representing the 
ASD; B. Contrast medium injection into the LAA through a 13 French (F) TorqView 
sheath in a right anterior oblique projection; C. Implantation of a 28 mm Amplatzer 
Cardiac Plug (ACP) through this sheath; D. Implantation of a 40 mm Amplatzer 
Septal Occluder (ASO) through the same sheath in a left anterior oblique projection. 
The right atrium (RA) is filled with contrast medium; E. Same view during the 
levophase with the left atrium (LA) delineated (dotted line) by contrast medium; F. 
Three-dimensional (3-D) transesophageal echocardiography (TEE) before the 
procedure depicting the ASD; G. Two-dimensional (2-D) TEE before the procedure 
indicating an ASD diameter of 28 mm; H. 2-D TEE at 11-month follow-up depicting 
the ASD and LAA occluders; I. 3-D TEE at 11-month follow-up. The ASO occludes 
the ASD completely without evidence of thrombus. 
 
 
Figure 2. Transesophageal echocardiography of a 53-year-old woman with exertional 
dyspnea and chest pain and a newly detected secundum atrial septal defect (ASD) as 
well as a patent foramen ovale (PFO) but no history of atrial fibrillation. The coronary 
arteries were normal on the incidental angiogram. The insert shows the result after 
simulatenous device closure of ASD (26 mm Amplatzer Septal Occluder), PFO (30 
mm Amplatzer Cribriform Occluder), and left atrial appendage (LAA, 22 mm 
Amplatzer Amulet) Occluder; LV — left ventricle; RV — right ventricle. 
 
Figure 3. Simultaneous closure of patent foramen ovale (PFO), atrial septal defect 
(ASD), and left atrial appendage (LAA) in patient of Figure 2; A. Sizing balloon in 
PFO; B. Sizing balloon in ASD, wire through PFO; C. Contrast medium injection into 
 LAA through 12 French (F) TorqVue sheath in a right anterior oblique projection; D. 
LAA occluded (with 22 mm Amplatzer Amulet Occluder); E. Final result: LAA 
occluded with 22 mm Amplatzer Amulet Occluder (22), then PFO occluded with 30 
mm Amplatzer Cribriform Occluder (30), and finally ASD occluded with 26 mm 
Amplatzer Septal Occluder (26). Left anterior oblique projection; LA — left atrium; 
RA — right atrium. 
 
Figure 4. Simultaneous closure of the left atrial appendage (LAA) and a newly 
detected double atrial septal defect (ASD) in a 64-year-old male with dyspnea but no 
atrial fibrillation. All devices were implanted through the same 14 French TorqVue 
sheath; A. 40 mm Amplatzer Septal Occluder (ASO, 40), 18 mm ASO (18), and 16 
mm Amplatzer Amulet Occluder (16) depicted in a in a left anterior oblique 
projection. The right atrium (RA) and in the insert the left atrium (LA) are filled with 
contrast medium; B. Double ASD in a transesophageal echocardiography (TEE) 
before the intervention; C. Double ASD in a three-dimensional TEE four months after 
the intervention with the two ASOs in place. 
 
 




